Premium
Progressive multifocal leukoencephalopathy after T‐cell replete HLA‐haploidentical transplantation with post‐transplantation cyclophosphamide graft‐versus‐host disease prophylaxis
Author(s) -
Ikegawa Shuntaro,
Fujii Nobuharu,
Tadokoro Koh,
Sato Kota,
Iwamoto Miki,
Matsuda Masayuki,
Inomata Tomoko,
Sugiura Hiroyuki,
Asano Takeru,
Yoshida Shohei,
Nishimori Hisakazu,
Matsuoka Kenichi,
Maeda Yoshinobu
Publication year - 2018
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12850
Subject(s) - medicine , progressive multifocal leukoencephalopathy , transplantation , cyclophosphamide , leukoencephalopathy , immunosuppression , graft versus host disease , human leukocyte antigen , immunology , disease , multiple sclerosis , antigen , chemotherapy
A 52‐year‐old man suffered from progressive multifocal leukoencephalopathy ( PML ) after human leukocyte antigen ( HLA )‐haploidentical transplantation with post‐transplantation cyclophosphamide ( PTCY ). Mirtazapine, mefloquine, and cytarabine failed to improve his symptoms, and he finally died 4.5 months after PML onset. This is the first case report of a patient with PML after HLA ‐haploidentical transplantation with PTCY . Although T‐cell replete HLA ‐haploidentical transplantation with PTCY has enabled early immune reconstitution, PML should be considered if a patient's mental condition deteriorates.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom